Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Leukemia 46Lymphoma 12Burkitt Lymphoma 7Leukemia, Promyelocytic, Acute 6Neoplasm, Residual 5Leukemia, Biphenotypic, Acute 5Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Dendritic Cell Sarcoma, Interdigitating 2Thrombocytopenia 1Rare Diseases 1Psoriasis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Ovarian Neoplasms 1Oligodendroglioma 1Neutropenia 1Neoplasms 1Mucositis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1

Interventions

Cytarabine 272Cyclophosphamide 136fludarabine phosphate 127Azacitidine 117Peripheral Blood Stem Cell Transplantation 95Busulfan 93Filgrastim 80Decitabine 79fludarabine 78Mycophenolic Acid 78Idarubicin 76Etoposide 76Whole-Body Irradiation 75Daunorubicin 72Tacrolimus 71Cyclosporine 64Methotrexate 62Mitoxantrone 57Clofarabine 55Antilymphocyte Serum 55Granulocyte Colony-Stimulating Factor 51Gemtuzumab 50Melphalan 49venetoclax 48Radiotherapy 30sargramostim 28Injections 25Bortezomib 25thymoglobulin 24aldesleukin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid, Acute × Mercaptopurine × Clear all
NCT00136084 2012-12-05

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

St. Jude Children's Research Hospital

Phase 3 Completed
238 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Myeloid, Acute

NCT00962767 2009-08-20

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
168 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡